Dynamic Technology Lab Private LTD Nektar Therapeutics Transaction History

Dynamic Technology Lab Private LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$3.04 - $5.14 $157,961 - $267,079	51,961 New	51,961 $166,000
Q3 2021 Nov 15, 2021	SELL	$13.07 - $18.84 $281,044 - $405,116	-21,503 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$16.52 - $20.4 $355,229 - $438,661	21,503 New	21,503 $369,000
Q4 2020 Feb 11, 2021	SELL	$15.77 - $19.03 $202,597 - $244,478	-12,847 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$16.59 - $24.79 $213,131 - $318,477	12,847 New	12,847 $213,000
Q2 2020 Aug 14, 2020	SELL	$16.86 - $23.44 $190,029 - $264,192	-11,271 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$14.47 - $27.96 $163,091 - $315,137	11,271 New	11,271 $201,000
Q4 2018 Feb 13, 2019	SELL	$30.43 - $56.65 $382,109 - $711,354	-12,557 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$46.46 - $68.49 $583,398 - $860,028	12,557 New	12,557 $766,000
Q1 2018 May 14, 2018	SELL	$57.4 - $108.44 $196,537 - $371,298	-3,424 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$23.02 - $60.5 $78,820 - $207,152	3,424	3,424 $205,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Dynamic Technology Lab Private LTD, based on Form 13F filings with the SEC.

Stay updated on Dynamic Technology Lab Private LTD with notifications on news.